Department of Medicine, University of Rochester School of Medicine and Dentistry, United States.
Vaccine. 2010 Feb 10;28(6):1477-80. doi: 10.1016/j.vaccine.2009.11.063. Epub 2009 Dec 8.
Human metapneumovirus (hMPV) is a significant cause of respiratory illness in children and adults. Presently, there are no human data regarding the role of antibody for protection against hMPV illness. Therefore, we measured serum and nasal antibody titers against hMPV by EIA and neutralization assay at baseline in hMPV infected adults compared with subjects who remained uninfected. Antibody titers were also compared in patients with mild and severe illness. Mean serum binding and neutralizing antibody titers of hMPV infected subjects were significantly lower compared to uninfected subjects. Seventy-one percent of subjects with titers <or=10.5 (log2) were infected compared to 36% with titers >10.5, p=0.003. There was no difference in the mean acute antibody titers for patients with mild compared to severe illness. Serum antibody may play a role in protection from hMPV infection supporting the development of an hMPV vaccine that stimulates humoral immunity.
人偏肺病毒（hMPV）是导致儿童和成人呼吸道疾病的重要原因。目前，尚无针对人偏肺病毒疾病的抗体保护作用的人体数据。因此，我们通过 EIA 和中和试验测量了基线时感染 hMPV 的成年人与未感染者的血清和鼻抗体滴度。我们还比较了轻症和重症患者的抗体滴度。与未感染者相比，hMPV 感染者的血清结合和中和抗体滴度明显较低。与滴度≤10.5（log2）的受试者相比，滴度＞10.5 的受试者中有 71%被感染，p=0.003。轻症患者的平均急性抗体滴度与重症患者没有差异。血清抗体可能在预防 hMPV 感染中发挥作用，支持开发刺激体液免疫的 hMPV 疫苗。
